NeoGenomics, Inc. (OQ:NEO)

Business Focus: Medical & Diagnostic Laboratories

Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 28, 2020 07:00 am ET
Jul 20, 2020 07:00 am ET
NeoGenomics Announces Board Appointments
FT MYERS, FL / ACCESSWIRE / July 20, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today changes in the composition and certain roles of its Board of Directors.
Jul 01, 2020 07:00 am ET
NeoGenomics Schedules its Second Quarter Earnings Release for July 28, 2020
FT. MYERS, FL / ACCESSWIRE / July 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020.
Jun 29, 2020 07:00 am ET
NeoGenomics Launches Comprehensive Suite of Solid Tumor Liquid Biopsy Tests for Cancer Patients
FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases. With the addition of these new testing capabilities, physicians can now rely on NeoGenomics to deliver biomarker information from potentially any patient with a solid tumor or hematologic malignancy even when a tissue biopsy is not possible.
Jun 01, 2020 04:05 pm ET
NeoGenomics To Virtually Participate In Fireside Chat At The 40th Annual William Blair Growth Stock Conference
FT. MYERS, FL / ACCESSWIRE / June 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer and Bill Bonello, President Informatics Division, Director of Investor Relations, will be participating in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Wednesday, June 10, 2020 at 8:40am CT.
May 26, 2020 07:20 am ET
NeoGenomics To Virtually Participate In 17th Annual Craig-Hallum Institutional Investor Conference
FT. MYERS, FL / ACCESSWIRE / May 26, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Kathryn McKenzie, Chief Financial Officer and Bill Bonello, President Informatics Division, Director of Investor Relations, will be participating in virtual meetings at the 17th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 27, 2020.
May 11, 2020 04:05 pm ET
NeoGenomics To Virtually Participate In Fireside Chat At BofA Securities 2020 Health Care Conference
FT. MYERS, FL / ACCESSWIRE / May 11, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Bill Bonello, President Informatics Division, Director of Investor Relations, will be participating in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 3:40pm ET.
May 05, 2020 08:00 am ET
NeoGenomics and Bayer Collaborate to Offer NTRK Testing for Certain Colorectal and Thyroid Cancer Patients
FT. MYERS, FL / ACCESSWIRE / May 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced a collaboration with Bayer (BAYN) to facilitate an RNA-based Neurotrophic Tropomyosin-Receptor Kinase (NTRK) testing for certain colorectal and thyroid cancer patients. All eligible patients who enroll and opt-in to a Sponsored Testing Program will receive testing at no cost to themselves or their insurance. Bayer will cover the total cost of this test regardless of the results and treatment decision.
Apr 30, 2020 06:00 am ET
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
FORT MYERS, FL / ACCESSWIRE / April 30, 2020 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced the pricing of concurrent underwritten public offerings of (a) 4,400,000 shares of its common stock at a public offering price of $28.50 per share for gross proceeds to NeoGenomics from the offering of $125.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NeoGenomics (the "common stock offering") and (b) $175,000,000
Apr 29, 2020 05:20 pm ET
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
FORT MYERS, FL / ACCESSWIRE / April 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced that it has commenced proposed underwritten public offerings of approximately $100,000,000 of newly issued shares of common stock (the "common stock offering") and $150,000,000 aggregate principal amount of convertible senior notes due 2025 (the "notes) (the "notes offering"). In addition, NeoGenomics expects to grant the underwriters of the offerings a 30-day option
Apr 28, 2020 07:00 am ET
Apr 09, 2020 07:00 am ET
NeoGenomics Provides COVID-19 Business Update
FT. MYERS, FL / ACCESSWIRE / April 9, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, provided a business update regarding the impact of the COVID-19 pandemic.
Apr 03, 2020 07:00 am ET
NeoGenomics Integrates HALO(R) From Indica Labs
FT. MYERS, FL / ACCESSWIRE / April 3, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused testing services, today announced that it has integrated Indica Labs enterprise-level HALO AP™ image analysis platform for Image Analysis, Immunohistochemistry (IHC) and Multiplexing across its Clinical Services and Pharma Services businesses. The platform's robust workflow modules streamlines analysis algorithms and provides rapid, quantitative results for a multitude of tissue types.
Apr 01, 2020 07:00 am ET
NeoGenomics Schedules its First Quarter Earnings Release for April 28, 2020
FT. MYERS, FL / ACCESSWIRE / April 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its first quarter 2020 financial results on Tuesday, April 28, 2020.
Mar 02, 2020 07:00 am ET
NeoGenomics Announces Three-Year Contract to be Cornerstone Oncology and Cancer Testing Laboratory for Large, National Group Purchasing Organization
FT. MYERS, FL / ACCESSWIRE / March 2, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that the company has been awarded a three-year contract with HealthTrust Purchasing Group (HPG). Effective March 1, 2020, NeoGenomics will serve as the cornerstone laboratory for HPG's Specialized Reference Laboratory for Oncology & Cancer Genetics, a newly-created category for oncology diagnostics in personalized medicine.
Feb 28, 2020 07:00 am ET
NeoGenomics To Present At 41st Annual Raymond James Institutional Investor Conference
FT. MYERS, FL / ACCESSWIRE / February 28, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Kathryn McKenzie, Chief Financial Officer and Bill Bonello, President Informatics Division, Director of Investor Relations, will be presenting at the 41st Annual Raymond James Institutional Investor Conference on Monday, March 2, 2020 at 8:40am ET in Orlando, FL.
Feb 27, 2020 07:08 am ET
Feb 06, 2020 07:00 am ET
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2019 Earnings Release for February 27, 2020
FT. MYERS, FL / ACCESSWIRE / February 6, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, February 27, 2020.
Feb 05, 2020 07:00 am ET
NeoGenomics Announces Leadership Appointments
FT. MYERS, FL / ACCESSWIRE / February 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today three important leadership appointments.
Jan 30, 2020 11:30 am ET
GEOPOLITICAL EVENTS TO CAST A LONG SHADOW: The February 6th Groundhog Investment Forum Examines the 2020 Outlook for Stocks in a Hyper-Headlines Year
From the U.S. Presidential election and Fed rates forecasts to Brexit, from the virus outbreak in China to wildfires in Australia, 2020 has begun with a flurry of news and promises to be a year of fast and furious headlines. How do corporate leaders adjust and what are the impacts for domestic companies? The 27th annual Emerald Asset Management Groundhog Investment Forum, being held on February 6th in Philadelphia, brings together corporate leaders, Emerald’s team of portfolio managers and analysts and industry professionals to chart the critical investment themes and tre
Jan 17, 2020 10:45 am ET
2020 OUTLOOK AND INSIGHTS: Investment Trends and Themes to be Highlighted at the Emerald Groundhog Day Investment Forum
Join Emerald Asset Management for the 27th annual Emerald Groundhog Day Investment Forum on February 6th in Philadelphia. The Forum is the unofficial kick-off to the year ahead as Emerald’s team of analysts and portfolio managers will present their key investment themes and trends for 2020, focusing on these key sectors:
Jan 10, 2020 08:40 am ET
NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million
Significantly Enhances Next Generation Sequencing Capabilities for Pharmaceutical Customers
Nov 06, 2019 04:05 pm ET
NeoGenomics To Participate In Fireside Chat At Stephens 21st Annual Investment Conference
FT. MYERS, FL / ACCESSWIRE / November 6, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be participating in a fireside chat at the Stephens 21st Annual Investment Conference on Wednesday, November 13, 2019 at 1:00pm CT in Nashville, TN.
Oct 29, 2019 07:00 am ET
Oct 01, 2019 04:05 pm ET
NeoGenomics Schedules its Third Quarter Earnings Release for October 29, 2019
FT. MYERS, FL / ACCESSWIRE / October 1, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its Third quarter 2019 financial results on Tuesday, October 29, 2019.
Sep 25, 2019 04:05 pm ET
NeoGenomics To Present At 2019 Cantor Global Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / September 25, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:45pm ET in New York, NY.
Sep 03, 2019 04:15 pm ET
NeoGenomics to Participate in Two Upcoming September Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / September 3, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be participating in the following September Conferences:
Aug 08, 2019 08:45 am ET
NeoGenomics Announces Leadership Transition and Reiterates Recently Increased 2019 Financial Guidance
FT. MYERS, FL / ACCESSWIRE / August 8, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, this morning filed an 8-K with the Securities and Exchange Commission announcing the retirement of Sharon Virag, Chief Financial Officer effective today. The company will begin a Chief Financial Officer search in due course.
Jul 31, 2019 07:00 am ET
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore
FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD® Laboratories central lab in Singapore.
Jul 30, 2019 07:00 am ET
NeoGenomics Reports 50% Revenue Growth to Record $102 Million in the Second Quarter
FORT MYERS, FL / ACCESSWIRE / July 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetics testing services, today announced second-quarter and first-half results for the period ended June 30, 2019.
Jul 09, 2019 07:00 am ET
NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida
FT. MYERS, FL / ACCESSWIRE / July 9, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it intends to build a leading-edge cancer diagnostics testing facility and new global business headquarters in Fort Myers, Florida.
Jul 01, 2019 04:01 pm ET
NeoGenomics Schedules its Second Quarter Earnings Release for July 30, 2019
FT MYERS, FL / ACCESSWIRE / July 1, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2019 financial results on Tuesday, July 30, 2019.
Jun 27, 2019 04:01 pm ET
NeoGenomics Announces New $250 Million Credit Agreement
FORT MYERS, FL / ACCESSWIRE / June 27, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that the company has entered into a new $250 million five-year Senior Secured Credit Agreement (the "New Credit Agreement") consisting of a $100 million Revolving Credit Facility, a $100 million Initial Term Loan, and a $50 million Delayed Draw Term Loan ("DDTL") which is available for 18 months. PNC Capital Markets LLC and PNC Bank, National Association acted as lead arranger and administrative agent
May 30, 2019 04:05 pm ET
NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference
FT. MYERS, FL / ACCESSWIRE / May 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 39th Annual William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 10:40am CT in Chicago, IL.
May 28, 2019 06:00 am ET
NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation
FT. MYERS, FL / ACCESSWIRE / May 28, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced availability of the QIAGEN therascreen® PIK3CA RGQ PCR test from QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for post-menopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. This PIK3CA assay is a companion diagnostic test recently approved by the FDA
May 23, 2019 04:30 pm ET
NeoGenomics To Attend The 16th Annual Craig-Hallum Institutional Investor Conference
FT. MYERS, FL / ACCESWIRE / May 23, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chief Executive Officer, Sharon Virag, Chief Financial Officer, and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be conducting one-on-one meetings with investors at the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019 in Minneapolis, MN.
May 21, 2019 08:10 pm ET
NeoGenomics Announces Pricing on Public Offering of Common Stock
FT. MYERS, FL / ACCESSWIRE / May 21, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $21.25 per share. Gross proceeds to NeoGenomics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NeoGenomics, are expected to be $148,750,000. All shares of common stock to be sold in the offering are being sold by NeoG
May 20, 2019 04:12 pm ET
NeoGenomics Announces Proposed Public Offering of Common Stock
FT. MYERS, FL / ACCESSWIRE / May 20, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of approximately $150,000,000 of newly issued shares of common stock. All shares of common stock to be sold in the offering are being sold by NeoGenomics. In addition, NeoGenomics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price, less underwriting discount
Apr 30, 2019 07:00 am ET
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter
FT. MYERS, FL / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019.
Apr 03, 2019 04:35 pm ET
NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019
FT. MYERS, FL / ACCESSWIRE / April 3, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its first quarter 2019 financial results on Tuesday, April 30, 2019.
Apr 02, 2019 05:20 pm ET
NeoGenomics to Present at 18th Annual Needham & Company Health Care Conference
FT. MYERS, FLORIDA / ACCESSWIRE / April 2, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Sharon Virag, Chief Financial Officer, and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 18th Annual Needham & Company Health Care Conference on Tuesday, Apr. 9, 2019 at 4:10pm ET in New York, NY.
Mar 28, 2019 07:20 am ET
Report: Developing Opportunities within Carter's, Ingredion, NeoGenomics, American Financial Group, Inogen, and Forrester Research — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Carter's, Inc. (NYSE:CRI), Ingredion Incorporated (NYSE:INGR),...
Mar 11, 2019 07:00 am ET
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R)
FT. MYERS, FL / ACCESSWIRE / March 11, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy TECENTRIQ® (atezolizumab) used in combination with chemotherapy. TECENTR
Mar 07, 2019 04:50 pm ET
NeoGenomics To Present At 39th Annual Cowen and Company Health Care Conference
FT MYERS, FL / ACCESSWIRE / March 7, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Sharon Virag, Chief Financial Officer, and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 39th Annual Cowen and Company Health Care Conference on Tuesday, Mar. 12, 2019 at 10:00 am ET in Boston.
Feb 19, 2019 07:00 am ET
NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2018. Fourth Quarter 2018 Highlights: Consolidated revenue increased 24.5% to $76.5...
Jan 28, 2019 07:00 am ET
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2018 Earnings Release for February 19, 2019
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its fourth quarter and fiscal year 2018 financial results on Tuesday, February 19, 2019. The Company has...
Jan 18, 2019 07:40 am ET
Report: Developing Opportunities within Macerich, Illinois Tool Works, NeoGenomics, Bunge, Dolby Laboratories, and Cracker Barrel Old Country Store — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Macerich Company (NYSE:MAC), Illinois Tool Works Inc. (NYSE:ITW),...
Jan 08, 2019 04:58 pm ET
NeoGenomics Set to Join S&P SmallCap 600
NEW YORK, Jan. 8, 2019 /PRNewswire/ -- NeoGenomics Inc. (NASD: NEO) will replace Engility Holdings Inc. (NYSE: EGL) in the S&P SmallCap 600 effective prior to the open of trading on Monday, January 14, 2019. S&P MidCap 400 constituent Science Applications International Corp. (NYSE: SAIC) is acquiring Engility Holdings in a deal expected to close on January 11 pending final conditions....
Dec 13, 2018 07:00 am ET
NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the appointment of Lawrence M. Weiss, M.D. as Chief Scientific Officer. Dr. Weiss joined NeoGenomics and has served as Medical Director...
Dec 12, 2018 07:35 am ET
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of the Company by GE Medical Systems Information...
Dec 11, 2018 04:10 pm ET
NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that GE Medical Systems Information Technologies, Inc. (“GE Info Tech”) intends to offer for sale in an underwritten secondary offering...
Dec 10, 2018 09:10 am ET
NeoGenomics Completes Acquisition of Genoptix, Inc.
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix, Inc. for $125 million in cash, as adjusted by working capital...
Nov 30, 2018 05:01 pm ET
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer...
Nov 30, 2018 04:04 pm ET
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of cancer-focused genetic testing services, will ensure Day-One patient access to FDA-approved molecular tests paired with newly approved drugs for cancer.
Nov 12, 2018 07:35 am ET
Research Report Identifies Ironwood Pharmaceuticals, The AES, Accuray, Ball, Park Hotels & Resorts, and NeoGenomics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), The AES Corporation...
Oct 30, 2018 07:00 am ET
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2018. Third Quarter 2018 Highlights: •   17% increase in consolidated revenue  •   14% increase in...
Oct 23, 2018 07:00 am ET
NeoGenomics Signs Definitive Agreement to Acquire Genoptix
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics...
Oct 18, 2018 09:10 am ET
Consolidated Research: 2018 Summary Expectations for MaxLinear, NeoGenomics, Intrepid Potash, Glu Mobile, Ingles Markets, and Ball — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MaxLinear, Inc (NYSE:MXL), NeoGenomics, Inc. (NASDAQ:NEO), Intrepid...
Oct 01, 2018 07:00 am ET
NeoGenomics Schedules its Third Quarter Earnings Release for October 30, 2018
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its third quarter 2018 financial results on Tuesday, October 30, 2018. The Company has scheduled a web-cast...
Sep 24, 2018 07:00 am ET
NeoGenomics Announces Participation in NCI-MATCH Clinical Trial
NeoGenomics Laboratories, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131)...
Sep 12, 2018 08:14 am ET
NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has been awarded a group purchasing agreement for clinical reference laboratory testing services with Premier. Effective,...
Aug 27, 2018 08:00 am ET
Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball Corporation (NYSE:BLL), Aethlon Medical, Inc. (NASDAQ:AEMD),...
Aug 09, 2018 08:40 pm ET
NeoGenomics Announces Pricing on Public Offering of Common Stock
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of its underwritten public offering of 9,800,000 shares of its common stock at a public offering price of $12.75 per share....
Aug 06, 2018 04:19 pm ET
NeoGenomics Announces Proposed Public Offering of Common Stock
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of approximately $125,000,000 of newly issued shares of common stock. NeoGenomics...
Jul 24, 2018 07:00 am ET
NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2018. Second Quarter 2018 Highlights: •  9% increase in consolidated revenue; 12% excluding...
Jul 02, 2018 04:05 pm ET
NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2018 financial results on Tuesday, July 24, 2018. The Company has scheduled a web-cast and...
Jun 25, 2018 04:05 pm ET
NeoGenomics Redeems 100% of Series A Redeemable Preferred Stock
NeoGenomics, Inc. (NASDAQ:NEO) (the “Company”), a leading provider of cancer-focused genetic testing services, announced today that it redeemed 6,864,000 million shares of Series A Redeemable Preferred Stock (“Series A Preferred Stock”) held by an...
Jun 21, 2018 08:00 am ET
Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ABIOMED, Inc. (NASDAQ:ABMD), Avid Technology, Inc. (NASDAQ:AVID), Unit...
Jun 01, 2018 08:00 am ET
PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and NeoGenomics Laboratories, Inc., a leading provider of cancer-focused genetic testing services, are forming a strategic alliance to provide a...
May 25, 2018 04:05 pm ET
NeoGenomics to Participate In Two Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that company management will be participating in the following investor conferences during May and June. 15th Annual Craig-Hallum...
May 01, 2018 07:45 am ET
Detailed Research: Economic Perspectives on NeoGenomics, Illinois Tool Works, Carriage Services, Gorman-Rupp, Fiesta Restaurant Group, and American Financial Group — What Drives Growth in Today's Comp
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NeoGenomics, Inc. (NASDAQ:NEO), Illinois Tool Works...
May 01, 2018 07:00 am ET
NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter 2018.First Quarter 2018 Highlights:10% increase in consolidated revenue; 14% excluding PathLogic 15%...
Apr 02, 2018 05:00 pm ET
NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services,announced today that it plans to release its first quarter 2018 financial results on Tuesday, May 1, 2018.The Company has scheduled a web-cast and...
Mar 20, 2018 07:00 am ET
NeoGenomics Announces Executive Appointments
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of George Cardoza as President of the Pharma Services Division and Sharon Virag as Chief Financial Officer. Ms. Virag...
Mar 19, 2018 08:25 am ET
Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forw
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chatham Lodging Trust (REIT) (NYSE:CLDT), Independent...
Mar 07, 2018 06:13 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating NeoGenomics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, March 7, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of NeoGenomics, Inc. (NASDAQ: NEO). ...
Feb 21, 2018 07:20 am ET
NeoGenomics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / NeoGenomics, Inc. (NASDAQ: NEO) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 10:00 AM Eastern Time.
Feb 21, 2018 07:00 am ET
NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017.Fourth Quarter 2017 Highlights:18.7% increase in clinical genetic testing...
Jan 30, 2018 07:00 am ET
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2017 Earnings Release for February 21, 2018
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services,announced today that it plans to release its fourth quarter and fiscal year 2017 financial results on Wednesday, February 21, 2018.The Company has...
Jan 09, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty — What Drives Growth in Today's Competitive Landscape
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fluidigm Corporation (NASDAQ:FLDM), Stemline Therapeutics, Inc....
Dec 06, 2017 07:00 am ET
NeoGenomics Announces Six Clinical Data Presentations to be Made at the American Society of Hematology Meeting
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that its physicians and scientists will present four posters and deliver two oral presentations at the American Society of Hematology's...
Dec 05, 2017 07:00 am ET
NeoGenomics Joins Thermo Fisher Scientific's Companion Diagnostic Center of Excellence Program with the Launch of Oncomine Dx Target Test
NeoGenomics, Inc. (NASDAQ: NEO), a leading global specialty oncology testing laboratory, has signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program (COEP). NeoGenomics is...
Nov 09, 2017 07:00 am ET
NeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
NeoGenomics Inc. (NASDAQ: NEO), a leading global specialty oncology testing laboratory, opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community....
Oct 25, 2017 07:00 am ET
NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2017.Third Quarter 2017 Highlights:17% increase in clinical genetic testing volume(1)4% increase in...
Oct 24, 2017 09:00 am ET
NeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical Trials
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services in the United States, announced today that it has opened its first international laboratory facility in Rolle, Switzerland, in the Canton of Vaud, just...
Oct 12, 2017 04:01 pm ET
NeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 Guidance
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it expects to report Quarter 3 revenue of approximately $63.1 million and Adjusted EBITDA(1) of approximately $6.0 million. Clinical...
Sep 28, 2017 07:00 am ET
NeoGenomics Schedules its Q3 2017 Earnings Release for October 25, 2017
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its third quarter 2017 financial results on Wednesday, October 25, 2017.The Company has scheduled a web-cast and conference call to discuss their Q3 2017 results on Wednesday,...
Sep 11, 2017 03:04 pm ET
NeoGenomics Reports on Impacts from Hurricane Irma
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that Hurricane Irma had minimal impacts to its Fort Myers, FL facility. In preparation for the storm, in order to ensure continuous,...
Jul 25, 2017 07:00 am ET
NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2017.Second Quarter 2017 Highlights:16% increase in clinical genetic testing volume(1)5% increase in...
Jun 28, 2017 07:00 am ET
NeoGenomics Schedules its Q2 2017 Earnings Release for July 25, 2017
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its second quarter 2017 financial results on Tuesday, July 25, 2017.The Company has scheduled a web-cast and conference call to discuss their Q2 2017 results on Tuesday, July...
Jun 02, 2017 07:00 am ET
NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an expansion of its Immuno-Oncology profiling test menu to reflect recent advances in immunotherapy. The Company has expanded its...
May 15, 2017 08:52 am ET
NeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced the presentation of results of a new clinical trial demonstrating that the sensitivity of its NeoLAB® Liquid Biopsy Prostatetest was 97% in...
Apr 26, 2017 07:00 am ET
NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2017.First Quarter 2017 Highlights:Integration of Clarient clients and facilities now complete 15%...
Apr 20, 2017 07:00 am ET
NeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Bill Bonello as Vice President, Treasurer, and Director of Corporate Development. From 2012 to present, Mr. Bonello...
Apr 14, 2017 04:01 pm ET
NeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2017 financial results on Wednesday, April 26, 2017.The Company has scheduled a web-cast and conference call to discuss their Q1 2017 results on Wednesday,...
Mar 13, 2017 07:00 am ET
NeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics, today announced that they have expanded...
Feb 22, 2017 07:00 am ET
NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.Fourth Quarter 2016 Highlights:140% increase in clinical genetic testing...
Feb 08, 2017 11:22 am ET
NeoGenomics Schedules its Q4 and Full Year 2016 Earnings Release for February 22, 2017
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter and full year 2016 financial results on Wednesday, February 22, 2017.The Company has scheduled a web-cast and conference call to discuss their fourth quarter...
Dec 22, 2016 09:51 am ET
NeoGenomics Closes $150 Million Senior Credit Facility
FT. MYERS, Fla., Dec. 22, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) (the "Company") announced today that it has closed on a new five year, $150 million senior secured credit facility, which includes a $75 million revolving loan and a $75 million term loan.  The new facility replaces the $54.6 million term loan and undrawn $25 million asset-based revolver previously in place.  ...
Oct 26, 2016 08:00 am ET
NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016
FT. MYERS, Fla., Oct. 26, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2016....
Oct 11, 2016 08:00 am ET
NeoGenomics Schedules its Q3 2016 Earnings Release for October 26, 2016
FT. MYERS, Fla., Oct. 11, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its third quarter 2016 financial results on Wednesday October 26, 2016....
Jul 26, 2016 08:00 am ET
NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
FT. MYERS, Fla., July 26, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2016....
Jul 05, 2016 08:00 am ET
NeoGenomics Schedules its Q2 2016 Earnings Release for July 26, 2016
FT. MYERS, Fla., July 5, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its second quarter 2016 financial results on Tuesday July 26, 2016....
Apr 27, 2016 08:00 am ET
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
FT. MYERS, Fla., April 27, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2016....
Apr 11, 2016 08:00 am ET
NeoGenomics Schedules its Q1 2016 Earnings Release for April 27, 2016
FT. MYERS, Fla., April 11, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2016 financial results on Wednesday April 27, 2016....
Mar 01, 2016 07:00 am ET
NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains
FT. MYERS, Fla., March 1, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015....
Jan 26, 2016 07:00 am ET
NeoGenomics Schedules its Q4 2015 and full year 2015 Earnings Release for March 1, 2016
FT. MYERS, Fla., Jan. 26, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2015 and full year 2015 financial results on Tuesday, March 1, 2016....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.